Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm neoadjuvant nab-paclitaxel + liposomal doxorubicin + cyclophosphamide for triple-negative breast cancer
ChiCTR2400093248Phase 4Not yet recruiting
- Sponsor
- Zunyi Medical University Affiliated Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel, pegylated liposomal doxorubicin and cyclophosphamide in triple-negative breast cancer (TNBC), sponsored by Zunyi Medical University Affiliated Hospital. Primary endpoint: Pathologic complete response. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
paclitaxelpegylated liposomal doxorubicincyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2400093248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093248.